-
公开(公告)号：EP3383853B1
公开(公告)日：2020-11-04
申请号：EP16871329.5
申请日：2016-11-29
IPC分类号： C07D401/14 , C07D413/14 , C07D401/06 , C07D409/14 , C07D417/14 , C07D451/02 , C07D487/08 , C07D211/10 , C07D211/16 , C07D211/44 , C07D211/46 , C07D211/54 , A61K31/4545 , A61P25/28 , A61P25/16 , A61P25/18 , A61P25/24 , A61P9/00 , A61P3/04 , A61P3/10
-
公开(公告)号：EP1879607B1
公开(公告)日：2014-11-12
申请号：EP06751833.2
申请日：2006-04-28
发明人： HOLLOWAY, M. Katharine , LIVERTON, Nigel, J. , LUDMERER, Steven, W. , MCCAULEY, John, A. , OLSEN, David, B. , RUDD, Michael, T. , VACCA, Joseph, P.
IPC分类号： A61K38/12
CPC分类号： C07K5/0808 , C07K5/0806 , C07K5/0812 , C07K5/0815 , C07K5/0821
-
公开(公告)号：EP2268285A1
公开(公告)日：2011-01-05
申请号：EP09714973.6
申请日：2009-02-12
发明人： MCCAULEY, John, A. , LIVERTON, Nigel, J. , HARPER, Steven , MCINTYRE, Charles, A. , RUDD, Michael, T.
IPC分类号： A61K31/70
CPC分类号： C07K5/0812 , A61K38/212 , A61K38/215 , A61K38/217 , C07K5/06078 , C07K5/0808 , A61K2300/00
摘要： A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, B, Z, M, W and n are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.
摘要翻译： 一类式（I）的大环化合物，其中R 1，R 3，R 4，R a，R b，A，B，Z，M，W和n在本文中定义，其可用作病毒蛋白酶的抑制剂 特别是丙型肝炎病毒（HCV）NS3蛋白酶。 还提供了用于合成和使用这种大环化合物治疗或预防HCV感染的方法。
-
公开(公告)号：EP1924593B9
公开(公告)日：2010-06-02
申请号：EP06787475.0
申请日：2006-07-14
发明人： HOLLOWAY, M. Katharine , LIVERTON, Nigel, J. , LUDMERER, Steven, W. , MCCAULEY, John, A. , OLSEN, David, B. , RUDD, Michael, T. , VACCA, Joseph, P. , MCINTYRE, Charles, J.
CPC分类号： C07K5/0808 , A61K38/00 , C07K5/0812 , C07K5/0827
-
公开(公告)号：EP3823629A1
公开(公告)日：2021-05-26
申请号：EP19838497.6
申请日：2019-07-15
IPC分类号： A61K31/661 , A61P31/14 , C07F9/40
-
公开(公告)号：EP3526196A1
公开(公告)日：2019-08-21
申请号：EP17860988.9
申请日：2017-10-09
发明人： RUDD, Michael, T. , MENG, Zhaoyang , WAI, Jenny , BENNETT, David Jonathan , BRNARDIC, Edward, J. , LIVERTON, Nigel, J. , STACHEL, Shawn, J. , HAN, Yongxin , TEMPEST, Paul , ZHU, Jiuxiang , XU, Xuewang , ZHU, Bin
IPC分类号： C07D211/08 , C07D211/14 , C07D401/02
-
7.发明公开
公开(公告)号：EP3393472A1
公开(公告)日：2018-10-31
申请号：EP16879916.1
申请日：2016-12-19
发明人： ACTON, John, J., III , BAO, Jianming , EGBERTSON, Melissa , GAO, Xiaolei , HARRISON, Scott T. , KNOWLES, Sandra L. , LI, Chunsing , LO, Michael Man-Chu , MAZZOLA, Robert D., Jr. , MENG, Zhaoyang , RUDD, Michael, T. , SELYUTIN, Oleg , TELLERS, David, M. , TONG, Ling , WAI, Jenny Miu-Chun
IPC分类号： A61K31/4155 , C07D231/10
摘要： The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
-
8.发明公开
公开(公告)号：EP3383853A1
公开(公告)日：2018-10-10
申请号：EP16871329.5
申请日：2016-11-29
IPC分类号： C07D239/42 , C07D239/02 , C07F9/02
摘要： In its many embodiments, the present invention provides certain substituted bispiperidinyl compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein ring A, ring B, R1, R2, R3, L, R4, X, Z, Li, Q and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver Χ-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
-
9.发明公开
公开(公告)号：EP3373935A1
公开(公告)日：2018-09-19
申请号：EP16864811.1
申请日：2016-11-07
发明人： RUDD, Michael, T. , BRNARDIC, Edward, J. , KIM, Yuntae , MEISSNER, Robert, S. , RADA, Vanessa , STACHEL, Shawn, J. , ZERBINATTI, Celina, V.
IPC分类号： A61K31/496 , C07D401/04 , C07D241/04
CPC分类号： C07D295/16 , A61K31/496 , A61P3/10 , A61P25/16 , A61P25/18 , A61P25/28 , C07D213/74 , C07D213/85 , C07D243/08 , C07D295/192 , C07D295/205 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/08 , C07D487/08 , C07D487/18 , C07D513/04 , C07D515/04
摘要： In its many embodiments, the present invention provides substituted cyanopyridine containing compounds of the Formula (I): and acceptable salts thereof, wherein R1, R2, R3, R4, R5, X, Y, Q, and the moiety are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
-
公开(公告)号：EP1913016B1
公开(公告)日：2013-01-16
申请号：EP06800513.1
申请日：2006-07-28
发明人： HOLLOWAY, M., Katharine , LIVERTON, Nigel, J. , MCCAULEY, John, A. , RUDD, Michael, T. , VACCA, Joseph, P. , LUDMERER, Steven, W. , OLSEN, David, B.
CPC分类号： C07K5/0812 , A61K38/00 , C07K5/0827
-
-
-
-
-
-
-
-
-
搜索结果
31 条记录 (耗时 0.025 秒)
